Receptor for abscisic acid (ABA) required for ABA-mediated responses such as stomatal closure and germination inhibition. Inhibits the activity of group-A protein phosphatases type 2C (PP2Cs) when activated by ABA (PubMed:19407143, PubMed:19855379, PubMed:19893533, PubMed:19898420, PubMed:23844015, PubMed:21658606). Can be activated by both (-)-ABA and (+)-ABA (PubMed:23844015). Homodimer (PubMed:21658606,PubMed:19898420). Binds ABA on one subunit only. Interacts with HAB1, ABI1 and ABI2, and possibly with other PP2Cs (PubMed:19407142, PubMed:19855379, PubMed:19874541, PubMed:19893533, PubMed:19898420). Binds to CARs protein in an ABA-independent manner, both at the plasma membrane and in the nucleus. Interacts directly with CAR1 and CAR4 (PubMed:25465408). Localizes at the plasma membrane in the presence of a CAR protein (e.g. CAR1 and CAR4). Upon interaction with ABA, the 'latch' and 'gate' loops change in conformation leading to a tight dimerization and the creation a surface that enables the receptor to dock into and inhibit the PP2C active site. The synthetic growth inhibitor pyrabactin inhibits ABA-binding and subsequent PP2Cs inhibitor properties. Belongs to the PYR/PYL/RCAR abscisic acid intracellular receptor family. Truncated N-terminus.